Tech Company Financing Transactions
Booster Therapeutics Funding Round
Booster Therapeutics, based in Berlin, secured $15 million from Apollo Health Ventures, Novo Holdings and private investors.
Transaction Overview
Company Name
Announced On
10/10/2024
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Seed
Investors
Apollo Health Ventures (Lead Investor)
Novo Holdings (Lead Investor)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Schlueterstr. 36
Berlin, 10629
Germany
Berlin, 10629
Germany
Phone
Undisclosed
Website
Email Address
Overview
Proteasomes degrade damaged, misfolded, or unnecessary proteins. To date, protein degradation therapeutics have mainly focused on tagging individual proteins of concern with a protein called ubiquitin, inducing their degradation. While this approach holds promise, it does not address the broader issue of natural proteasome dysfunction which affects many protein pathways and contributes to many major diseases. Our approach is designed to restore the proteasome's full potential with therapeutics to address complex diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Patrick Trojer
Co-Founder
Diogo Feleciano
Co-Founder
Darci Trader
VP - Bus. Development
João Ribas
Browse more venture capital transactions:
Prev: 10/10/2024: Scope3 venture capital transaction
Next: 10/10/2024: Suki venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs